Collaboration and License Agreement - Additional Information (Details) $ in Thousands, ¥ in Millions					1 Months Ended						3 Months Ended		7 Months Ended	9 Months Ended
	Oct. 31, 2021 USD ($)	Oct. 31, 2021 JPY (¥)	Jan. 01, 2019 USD ($)	Jan. 01, 2019 JPY (¥)	Jul. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 JPY (¥)	Oct. 31, 2021	Jun. 30, 2020 USD ($)	May 30, 2020	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Jul. 31, 2023 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Jul. 31, 2023 JPY (¥)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Feb. 28, 2023 USD ($)	May 31, 2020 USD ($)
Roche
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received											$ 138,626			$ 138,626
Roche | Combined licenses
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received											105,327			105,327
Roche | Transfer of clinical trial materials
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received											2,714			2,714
Roche | Completion of Continuing Trials
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received											30,585			30,585
Deferred revenue						$ 17,957					10,161			10,161			$ 11,820	$ 16,645
Deferred revenue, current											7,685			7,685
Deferred revenue, noncurrent											2,476			2,476
Roche | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received											134,600			134,600
Deferred revenue recognized											1,700	$ 112,300		11,800	$ 112,300
Roche | Collaboration and License Agreement | Research and development services member
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue recognized												4,300			4,300
Roche | Collaboration and License Agreement | Combined licenses
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue recognized												105,300			105,300
Roche | Collaboration and License Agreement | Transfer of clinical trial materials
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received											5,600			5,600
Deferred revenue recognized												2,700			2,700
Roche | Collaboration and License Agreement | Commercial Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestones Payments														1,172,000
Roche | Collaboration and License Agreement | Completion of Continuing Trials
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue						18,000					10,200			10,200
Deferred revenue, current						15,300					7,700			7,700
Deferred revenue, noncurrent						2,700					2,500			2,500
Roche | Collaboration and License Agreement | Product additional clinical development plan
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue receivable																			$ 4,000
Non-refundable payment received											4,000			4,000
Amount of additional consideration											4,000			4,000
Roche | Collaboration and License Agreement | Upfront non refundable first payment received
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received											125,000			125,000
Bristol-Myers Squibb Company
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received											50,000			50,000
Deferred revenue						27,354					12,787			12,787			$ 13,287	$ 26,988
Deferred revenue, current											12,787			12,787
Bristol-Myers Squibb Company | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration term expiration period										42 months
Initial nonrefundable upfront fee received									$ 50,000
Non-refundable payment received																				$ 50,000
Deferred revenue, current						27,400					12,800			12,800
Bristol-Myers Squibb Company | Collaboration and License Agreement | Product Research Activity [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue recognized											500	200		2,100	1,300
Bristol-Myers Squibb Company | Collaboration and License Agreement | Druggable Target
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue, triggered further development														1,000
Deferred revenue triggered recognized											0	0		1,000	0
Deferred revenue recognized											0	0		12,700	0
Option fee Received											250			250
Bristol-Myers Squibb Company | Collaboration and License Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received																				301,000
Bristol-Myers Squibb Company | Collaboration and License Agreement | Maximum | Research, Development and Regulatory Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received																				176,000
Bristol-Myers Squibb Company | Collaboration and License Agreement | Maximum | Commercial Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received																				$ 125,000
Ono Pharmaceutical Company Ltd | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Initial nonrefundable upfront fee received			$ 8,100	¥ 900
Collaboration term extended period								1 year
Second amendment agreement													In January 2023, the Company and Ono entered into a second amendment to the Ono Agreement whereby the Research Term, as defined in the Ono Agreement, was extended until July 31, 2023
Termination agreement description					In July 2023, Ono provided the Company with a formal notice to terminate the Ono Agreement without cause as defined in the Ono Agreement. As a result of this termination, all rights to the Polθ program have reverted to the Company.
Deferred Revenue, Additions	$ 900	¥ 100				$ 1,500	¥ 200
Deferred revenue recognized											$ 0	$ 0		$ 10,500	$ 0
Ono Pharmaceutical Company Ltd | Collaboration and License Agreement | Commercial Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received					$ 149,500								$ 149,500			¥ 17,210
Ono Pharmaceutical Company Ltd | Collaboration and License Agreement | Additional Research Service Milestone
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received					$ 6,500								$ 6,500			¥ 750